A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
about
An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies.Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.Antiviral activity of a single-domain antibody immunotoxin binding to glycoprotein D of herpes simplex virus 2.Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.Targeting malignant B cells with an immunotoxin against ROR1Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicityImmunogenicity of therapeutic recombinant immunotoxins.Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.Targeted toxins in brain tumor therapy.Novel antibody-based proteins for cancer immunotherapy.Trafficking and processing of bacterial proteins by mammalian cells: Insights from chondroitinase ABC.Improving the in vivo efficacy of an anti-Tac (CD25) immunotoxin by Pseudomonas exotoxin A domain II engineering.
P2860
Q34276680-74141B0A-3751-4E84-9E50-C85550985130Q34804520-42D39A34-510F-48B6-996B-44AD58DBDBFAQ34923432-1FED14DA-9C57-46EB-830C-1456398A94EBQ35018336-AE23D1BE-23F1-4782-A5C4-18FA17113E4AQ35023967-F88FE804-70D1-4E52-82D0-652AA4712F23Q35230663-158A46A8-2B35-4D5D-8361-5A221410D324Q35747230-3B7581D8-9A22-4C95-A4F1-106053A82FEDQ35969887-36CDD8B8-529A-4331-AE7F-A8212E77B145Q36485104-21EE6530-350D-41B6-928E-A461234CD69FQ36536466-1AC9A2B4-801A-46E0-8F66-C823AF5021CAQ36593468-E273BB30-4A05-448E-897A-E4E2BB2F56B5Q37209001-AB42B395-7D12-4BCD-9CF8-9F351AD6BFB3Q37859775-CC3C127E-827F-4303-B4D9-DA33B0BE7361Q37954275-25851B47-C375-487C-A5C5-DC658BBACB39Q38161370-117DE48D-BD45-4EC5-B95C-3525FE47D92CQ43646967-5BE08E41-1265-49A1-9DB9-B29D49E14B9FQ52716628-A5E75883-34DB-4E48-84AF-D9209435C80B
P2860
A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
A recombinant immunotoxin targ ...... gh antitumor activity in mice.
@en
A recombinant immunotoxin targ ...... gh antitumor activity in mice.
@nl
type
label
A recombinant immunotoxin targ ...... gh antitumor activity in mice.
@en
A recombinant immunotoxin targ ...... gh antitumor activity in mice.
@nl
prefLabel
A recombinant immunotoxin targ ...... gh antitumor activity in mice.
@en
A recombinant immunotoxin targ ...... gh antitumor activity in mice.
@nl
P2093
P1476
A recombinant immunotoxin targ ...... igh antitumor activity in mice
@en
P2093
Ira Pastan
Johanna K Hansen
Laiman Xiang
Masanori Onda
Richard Beers
P304
P356
10.1097/CJI.0B013E3181CD1164
P577
2010-04-01T00:00:00Z